NEW YORK (GenomeWeb News) – Crown Bioscience and Horizon Discovery today announced that they will partner on offering new in vivo X-MAN models as a service to Crown's customers.

Horizon's X-MAN cell lines are used for in vivo and in vitro drug discovery model validation. The Cambridge, UK-baed firm already offers more than 450 X-MAN cell lines, as well as more than 50 phenotypic cell-based assays, and its SyntheTx drug/RNAi screening platform.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.